Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Dermatology | Oncology | Family Medicine
Search Medical Condition
Melanoma Clinical Trials
A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (576) clinical trials
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
To compare overall survival (OS) of patients with resected Stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b or ipilimumab versus MK-3475 (pembrolizumab)
Pembrolizumab + Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma
The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma.
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination with Nivolumab in Select Advanced Cancers
The purpose of this study is to assess the safety, tolerability, and efficacy when combining INCB024360 and Nivolumab in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors
This is an open label, non-randomized, multi-center study. The primary purpose of the study is to evaluate the safety, tolerability and efficacy of Epacadostat and Durvalumab when given in combination in patients with Selected Advanced Solid Tumors.
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part B)
You are being asked to take part in this research study because you were diagnosed with a type of cancer called melanoma. Although your melanoma has been removed by surgery, you are at risk for having the melanoma come back (recur). People who are at risk for melanoma recurrence are ...
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)
The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)
This randomized phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances ...
CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01274338?term=E1609&rank=1
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in subjects with advanced or metastatic malignancies.
A Washington University research study seeks participants with melanoma.
The purpose of the study is to develop new tests to predict the outcome of immunotherapy. There are up to 2 study visits. There may be the opportunity to participate in additional visits in the future. Each visit will last 30 to 50 minutes. There will be urine collection, survey, ...
